Billy H T, Rimkus D R, Hartzman S, Latimer R G
Department of Surgical Education, Santa Barbara Cottage Hospital, California, USA.
Am Surg. 1995 Oct;61(10):882-8.
Technetium 99m sestamibi, a newer radionuclide agent, has shown promise in parathyroid scintigraphy. Recent studies using technetium 99m sestamibi in conjunction with subtraction iodine I123 imaging have demonstrated accuracy for localizing parathyroid glands in patients with hyperparathyroidism. The effectiveness of technetium 99m sestamibi scanning as a single agent was compared prospectively with conventional high resolution ultrasonography for the preoperative localization of abnormal parathyroid glands in patients with primary hyperparathyroidism. Seventeen patients with primary hyperparathyroidism had preoperative evaluation with high resolution ultrasonography and technetium 99m sestamibi radionuclide scanning. All patients underwent bilateral neck exploration. Ultrasound results were made available to the surgeon preoperatively; however, technetium 99m sestamibi results were withheld unless specifically asked for by the surgeon intraoperatively. Comparison of the imaging studies were correlated with the operative and histological findings. Of 17 patients, 12 had solitary adenomas and four had diffuse hyperplasia. In one patient no abnormal glands were discovered. In patients with technetium 99m sestamibi localization, a solitary adenoma was identified correctly in 10 of 12 patients (83%). Three of four patients with diffuse hyperplasia had parathyroid sestamibi scans showing nonfocal or diffuse uptake in multiple glands. High resolution ultrasonography correctly identified only six of 12 patients with solitary parathyroid adenomas (50%). Of the patients with diffuse hyperplasia, two ultrasound studies showed a single enlarged gland, one study was negative, and one localized two questionable, enlarged glands. Technetium 99m sestamibi is effective as a single agent for preoperative parathyroid scintigraphy.(ABSTRACT TRUNCATED AT 250 WORDS)
锝99m甲氧基异丁基异腈是一种较新的放射性核素药物,在甲状旁腺闪烁扫描术中显示出应用前景。近期使用锝99m甲氧基异丁基异腈联合减影碘I123成像的研究已证实,其在定位甲状旁腺功能亢进患者的甲状旁腺方面具有准确性。将锝99m甲氧基异丁基异腈扫描作为单一药物的有效性,与传统高分辨率超声进行了前瞻性比较,用于原发性甲状旁腺功能亢进患者术前异常甲状旁腺的定位。17例原发性甲状旁腺功能亢进患者接受了高分辨率超声和锝99m甲氧基异丁基异腈放射性核素扫描的术前评估。所有患者均接受双侧颈部探查。术前将超声结果提供给外科医生;然而,除非外科医生在术中特别要求,否则锝99m甲氧基异丁基异腈的结果不予提供。将影像学研究结果与手术及组织学发现进行关联比较。17例患者中,12例有孤立性腺瘤,4例有弥漫性增生。1例患者未发现异常腺体。在锝99m甲氧基异丁基异腈定位的患者中,12例患者中有10例(83%)正确识别出孤立性腺瘤。4例弥漫性增生患者中有3例甲状旁腺甲氧基异丁基异腈扫描显示多个腺体有非局灶性或弥漫性摄取。高分辨率超声仅正确识别出12例孤立性甲状旁腺腺瘤患者中的6例(50%)。在弥漫性增生患者中,两项超声检查显示一个腺体增大,一项检查为阴性,一项定位了两个可疑增大的腺体。锝99m甲氧基异丁基异腈作为单一药物用于术前甲状旁腺闪烁扫描术是有效的。(摘要截选至250字)